This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.